| Sep 4 |
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
|
| Aug 28 |
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
|
| Aug 20 |
IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript
|
| Aug 20 |
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 20 |
IceCure Medical GAAP EPS of -$0.14 misses by $0.07, revenue of $1.75M beats by $0.82M
|
| Aug 20 |
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
|
| Aug 14 |
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
|
| Aug 13 |
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
|
| Aug 7 |
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"
|
| Jul 22 |
IceCure presents hat-trick of positive trial data for cryoablation device
|
